Authors
Latest:
Eight Tips on Improving KOL EngagementGary Kaplan offers surveying tips to help identify both tactical and strategic initiatives required for a true key performance indicator.
Latest:
Supply Chain Integration or Bust… or BothThe recent formation of three mega supply-chain purchasing groups (Walgreen’s-AllianceBoots-AmerisourceBergen-Rite-Aid, McKesson-Celesio, CVS-Cardinal) denotes a shift in the balance of power between wholesalers, chains, generic pharmaceutical companies and branded pharma companies.
Latest:
Private Payers in Canada Embrace Product Listing AgreementsArvind Mani and Sherry O' Quinn outline the prevalence of private payer PLAs in Canada.
Latest:
The Digital Healthcare EvolutionBruno Villetelle discusses how Japanese companies like Takeda have begun to digitize in order to care for the country's aging population.
Latest:
What “Precision Medicine” Means for Rare DiseasesPresident Obama’s year-old, $200 million Precision Medicine initiative (PMI) seems to be doing exactly what was intended, writes Heather Gartman.
Latest:
What Errors Do We Miss in Clinical Trials?As new ICH GCP draft guidelines now require root cause analysis, novel methods for risk analysis and triage must be adopted in drug development.
Latest:
Beyond 2020: Building Strategic Coherence in the New Health EconomyPositioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
Latest:
Brexit Report: What's Next for the Industry?As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Latest:
The Great Life Sciences Regulatory RedressElvis Paćelat outlines some lessons from big pharma as medical device manufacturers succumb to new reporting obligations.
Latest:
March 2017: Big Data, Big Opportunity in Life SciencesThe big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
Coupon-Program Pivot: Meeting New Legal, Operational HurdlesPharma manufacturers may need to upgrade their coupon programs to accommodate for the emergence of copay accumulators and related benefit mechanisms.
Latest:
Disruptive Forces Driving a New Order in Healthcare Business ModelsSeveral factors are combining to change the definition of what healthcare truly is, and how it will be delivered and experienced in the next few years.
Latest:
Making the Most of Management ConsultingIntense regulatory demands, cost pressure, and the need to be ever more efficient has led to an upturn in the use of management consultants in the pharma & biotech sector, writes B.J. Richards.
Latest:
Raising the Stakes On Value-Based PricingThe importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .
Latest:
Pricing for Rare Disease and Curative Therapies: What’s Fair?There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.
Latest:
Data Unleashed: Cooperation Among CompetitorsCharting two years of collaborative progress in clinical trial data sharing.
Latest:
Closing the Gaps in Drug Chain of CustodyLimitations of the Drug Supply Chain Security Act for pharma-and three strategies to fix them.
Latest:
Alphabet’s Health Care Laundry ListWhen an 800-pound gorilla stakes a claim in an industry sector, the incumbents sit up and take notice-particularly when the gorilla is named Alphabet and is the parent company of Google. Cassie Arnold reports.
Latest:
Who Will Win the Race to Treat NASH?The liver disease non-alcoholic steatohepatitis (NASH) has become a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. The race is now to develop the first effective pharmacotherapy to treat it.
Latest:
Pharma’s Big Push for ValueAn “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.
Latest:
Making the Most Out of Your Real EstateAs companies look to raise capital, selling and then leasing back real estate is a tempting option and one that other industries are utilizing, writes Karen Williamson.
